The effect of duloxetine treatment on cognition in patients with fibromyalgia

Psychosomatic Medicine

Volumn 74, Issue 6, 2012, Pages 628-634

  Mohs, Richard ^a   Mease, Philip ^c,d   Arnold, Lesley M ^e   Wang, Fujun ^f   Ahl, Jonna ^b   Gaynor, Paula J ^e   Wohlreich, Madelaine M ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Lilly USA   (United States)

^c Swedish Medical Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f NONE

Author keywords

cognitive testing; duloxetine; fibromyalgia

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; AGED; ARTICLE; ATTENTION; BRIEF PAIN INVENTORY; COGNITION; CONTROLLED STUDY; DRUG EFFECT; EPISODIC MEMORY; EXECUTIVE FUNCTION; FEMALE; FIBROMYALGIA; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RECALL; WORKING MEMORY;

EID: 84863724845     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0b013e31825b9855     Document Type: Article

References (36)

1. Glass JM. Review of cognitive dysfunction in fibromyalgia: a convergence on working memory and attentional control impairments. Rheum Dis Clin North Am 2009;35:299-311.
2. Katz RS, Heard AR, Mills M, Leavitt F. The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia. J Clin Rheumatol 2004;10:53-8. (Pubitemid 38496092)
3. Landro NI, Stiles TC, Sletvold H. Memory functioning in patients with primary fibromyalgia and major depression and healthy controls. J Psychosom Res 1997;42:297-306. (Pubitemid 27186881)
4. Grace GM, Nielson WR, Hopkins M, Berg MA. Concentration and memory deficits in patients with fibromyalgia syndrome. J Clin Exp Neuropsychol 1999;21:477-87.
5. Ressler KJ, Nemeroff CB. Role of norepinephrine in the pathophysiology of neuropsychiatric disorders. CNS Spectr 2001;6:663-6.
6. Meneses A, Perez-Garcia G. 5-HT(1A) receptors and memory. Neurosci Biobehav Rev 2007;31:705-27.
7. Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heetan GJ, Booij J. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. Arch Gen Psychiatry 2001; 58:901-6. (Pubitemid 32937910)
8. Jann MW, Slade JH. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy 2007;27:1571-87. (Pubitemid 350060211)
9. Iyengar S,Webster AA, Hemrick-Luecke SK, Xu JY, Simmons RM. Efficacy of duloxetine, a potent and balanced serotonin-norepinephrine reuptake inhibitor in persistent pain models in rats. J Pharmacol Exp Ther 2004;311:576-84. (Pubitemid 39391542)
10. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, Rotz BT, Mohs RC. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007;164:900-9. (Pubitemid 46972905)
11. Arnold LM, Clauw D, Wang F, Ahl J, Gaynor PJ, Wohlreich MM. Flexible dosed duloxetine versus placebo in the treatment of fibromyalgia: a randomized, double-blind trial. J Rheumatol 2010;37:2578-86.
12. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 1990;33:160-72. (Pubitemid 20098653)
13. Cleeland CS, Ryan KM. Pain assessment: global use of the brief inventory. Ann Acad Med Singapore 1994;23:129-38.
14. Lezak MD. Neuropsychological Assessment. 3rd ed. New York, NY: Oxford University Press; 1995:438-45.
15. Savage RM, Gouvier WD. Rey Auditory-Verbal Learning Test: the effects of age and gender, norms for delayed recall and story recognition trials. Arch Clin Neuropsychol 1992;7:407-14.
16. Weschler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, TX: The Psychological Corp; 1997.
17. Ardila A. Normal aging increases cognitive heterogeneity: analysis of dispersion in WAIS-III scores across age. Arch Clin Neuropsychol 2007; 22:1003-11. (Pubitemid 350102024)
18. Reitan RM. The relation of the Trail Making Test to organic brain damage. J Consult Psychol 1955;19:393-4.
19. Reitan RM, Wolfson D. The Trail Making Test as an initial screening procedure for neuropsychological impairment in older children. Arch Clin Neuropsychol 2004;19:281-8. (Pubitemid 38316876)
20. Tombaugh TN. Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 2004;19:203-14. (Pubitemid 38316871)
21. Suhr JA. Neuropsychological impairment in fibromyalgia. Relation to depression, fatigue, and pain. J Psychosom Res 2003;55:321-9. (Pubitemid 38367756)
22. Walitt B, Roebuck-Spencer T, Bleiberg J, Foster G, Weinstein A. Automated neuropsychiatric measurements of information processing in fibromyalgia. Rheumatol Int 2008;28:561-6.
23. Park DC, Glass JM, Minear M, Crofford LJ. Cognitive function in fibromyalgia patients. Arthritis Rheum 2001;44:2125-33. (Pubitemid 33644057)
24. Dick B, Eccelston C, Crombez G. Attentional functioning in fibromyalgia, rheumatoid arthritis, and musculoskeletal pain patients. Arthritis Rheum 2002;47:639-44. (Pubitemid 35461317)
25. Glass JM, Park DC, Minear M, Crofford LJ. Memory beliefs and functions in fibromyalgia patients. J Psychosom Res 2005;58:236-s9.
26. Leavitt F, Katz RS. Distraction as a key determinant of impaired memory in patients with fibromyalgia. J Rheumatol 2006;33:127-32. (Pubitemid 43054292)
27. Stuss DT, Stethem LL, Pelchat G. Three tests of attention and rapid information processing. An extension. Clin Neuropsychol 1988;2:246-50.
28. Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills 1977;44:367-73. (Pubitemid 8087310)
29. Sletvold H, Stiles TC, Landro NI. Information processing in primary fibromyalgia, major depression, and healthy controls. J Rheumatol 1995; 22:137-42.
30. Siepmann T, Mueck-Weymann M, Oertel R, KirchW, Pittrow D, Siepmann M. The effects of venlafaxine on cognitive functions and quantitative EEG in healthy volunteers. Pharmacopsychiatry 2008;41:146-50.
31. Poirier MF, Galinowski A, Amado I, Longevialle R, Bourdel MC, Tournoux A, Serre C, Loo H. Double-blind comparative study of the action of repeated administration of milnacipran versus placebo on cognitive functions in healthy volunteers. Hum Psychopharmacol 2004; 19:1-7. (Pubitemid 38159269)
32. Kerr JS, Powell J, Hindmarch I. The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. Br J Clin Pharmacol 1996;42:239-41. (Pubitemid 26255073)
33. Salinsky M, Storzbach D, Munoz S. Cognitive effects of pregabalin in healthy volunteers. A double-blind, placebo-controlled trial. Neurology 2010; 74:755-61.
34. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 2nd ed. New York, NY: Oxford University Press; 1998.
35. Salthouse TA. What do adult age differences in the Digit Symbol Substitution Test reflect? J Gerontol 1992;47:121-8.
36. Joy S, Kaplan E, Fein D. Speed and memory in theWAIS III Digit Symbol-Coding subtest across the adult lifespan. Arch Clin Neuropsychol 2004; 19:759-67. (Pubitemid 39013341)